Goldman Sachs analyst Salveen Richter reiterated a Buy rating and $223.00 price target on Sarepta Therapeutics (NASDAQ: SRPT)The analyst comments ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE